Herceptin plus taxol highly effective in lower-risk breast cancer patients

98.7 percent are cancer free for at least 3 years

2013-12-11

(Press-News.org) Contact information: Jim Ritter
jritter@lumc.edu
708-216-2445
Loyola University Health System
Herceptin plus taxol highly effective in lower-risk breast cancer patients 98.7 percent are cancer free for at least 3 years MAYWOOD, Ill. – A remarkable 98.7 percent of certain lower-risk breast cancer patients were cancer free for at least three years after taking a combination of the drugs Herceptin and Taxol, a study has found.

The study is the first major trial to examine the Herceptin-Taxol combination in patients who have a type of breast cancer with the biology known as small, node-negative, HER2+. Results were presented during the 2013 San Antonio Breast Cancer Symposium.

"This is great news for patients and their physicians," said Kathy Albain, MD, of Loyola University Medical Center, who is one of the co-authors of the national multicenter study. "This study identifies a new treatment option for this population of patients that is highly effective and has minimal side effects." First author is Sara Tolaney, MD, of the Dana-Farber Cancer Institute.

About 1 in 4 breast patients have HER2+ breast cancer, meaning their cancer cells have a receptor protein on the surface known as HER2 (Human Epidermal growth factor Receptor 2).

Herceptin is part of the well-established standard-of-care for higher-risk HER2+ patients. But there currently is no single standard treatment patients with the for lower-risk HER2+ biology. In these patients, their tumors are small and the cancer has not spread to lymph nodes. Some of these patients currently are not receiving Herceptin, while others are being treated with Herceptin plus more toxic chemotherapy drugs.

The new study finds that an in-between treatment – Herceptin plus a single chemotherapy drug Taxol – is highly effective, with few adverse effects. Of the 406 patients studied, only 3.2 percent experienced severe neuropathy and only 0.5 percent experienced symptoms of congestive heart failure, which resolved after they discontinued Herceptin.

### Loyola enrolled patients in the trial, and Albain is principal investigator for the Loyola site. She is a professor in the Division of Hematology/Oncology at Loyola University Chicago Stritch School of Medicine, and directs Loyola's breast clinical research program.

ELSE PRESS RELEASES FROM THIS DATE:

Hydrogen-powered invasion

2013-12-11

Hydrogen-powered invasion The intestine is bustling with billions of intestinal bacteria that aid digestion and keep it healthy. A vast array of microorganisms (microbiota) colonise the intestine so densely that pathogens do not usually stand a chance of multiplying. ...

Scientists discover chemical modification in human malaria parasite DNA

2013-12-11

Scientists discover chemical modification in human malaria parasite DNA Findings by UC Riverside researchers could help build a new drug to kill the deadly parasite that is becoming resistant to existing drugs RIVERSIDE, Calif. -- Say "malaria" and ...

Incarceration has no effect on nonresident fathers' parenting

2013-12-11

Incarceration has no effect on nonresident fathers' parenting WASHINGTON, DC, December 11, 2013 — A prison sentence may not always have negative consequences for children of the incarcerated, says University of California, Irvine sociologist Kristin ...

Mothers that have a vaginal birth without epidural anesthesia are happier

2013-12-11

Mothers that have a vaginal birth without epidural anesthesia are happier An article published in the journal Nutricion Hospitalaria reveals that the attitude of healthcare personnel, along with starting early breast-feeding, are another ...

Study uncovers new evidence for assessing tsunami risk from very large volcanic island landslides

2013-12-11

Study uncovers new evidence for assessing tsunami risk from very large volcanic island landslides The risk posed by tsunami waves generated by Canary Island landslides may need to be re-evaluated, according to researchers at the National ...

Carbon capture technology could be vital for climate targets

2013-12-11

Carbon capture technology could be vital for climate targets The future availability of carbon capture and storage (CCS) will be pivotal in reaching ambitious climate targets, according to a new comprehensive study of future ...

Cancer 'avalanche effect' refuted

2013-12-11

Cancer 'avalanche effect' refuted First, the number of chromosomes in a cell changes, then an avalanche of further mutations occur that transform the cell into a cancer cell, according to a well-known - but untested - theory. A research group at Lund ...

Give future generations a chance: Support mothers to secure future public health

2013-12-11

Give future generations a chance: Support mothers to secure future public health Current approaches to curbing the global rise of chronic diseases, such as diabetes and heart disease, are failing, according to University of Southampton researchers. Writing ...

Personal care products are possible sources of potentially harmful parabens for babies

2013-12-11

Personal care products are possible sources of potentially harmful parabens for babies Through lotions, shampoos and other personal care products (PCPs), infants and toddlers are likely becoming exposed to potentially harmful substances, called parabens, ...

Antivirals for HCV improve kidney and cardiovascular diseases in diabetic patients

2013-12-11

Antivirals for HCV improve kidney and cardiovascular diseases in diabetic patients Researchers from Taiwan reveal that antiviral therapy for hepatitis C virus (HCV) improves kidney and cardiovascular outcomes for patients with diabetes. Results of the study published in Hepatology, ...